GRITSTONE ONCOLOGY INC's ticker is GRTS and the CUSIP is 39868T105. A total of 1 filers reported holding GRITSTONE ONCOLOGY INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $139 | +9.4% | 80,535 | +24.4% | 0.00% | – |
| Q2 2023 | $127 | -3.1% | 64,735 | +38.0% | 0.00% | – |
| Q1 2023 | $131 | +1.6% | 46,900 | +25.7% | 0.00% | – |
| Q4 2022 | $129 | -99.9% | 37,300 | 0.0% | 0.00% | – |
| Q3 2022 | $96,000 | +6.7% | 37,300 | 0.0% | 0.00% | – |
| Q2 2022 | $90,000 | -46.7% | 37,300 | -9.2% | 0.00% | – |
| Q1 2022 | $169,000 | -54.6% | 41,099 | +41.9% | 0.00% | – |
| Q4 2021 | $372,000 | +10.7% | 28,956 | -7.0% | 0.00% | – |
| Q3 2021 | $336,000 | -81.9% | 31,144 | -84.7% | 0.00% | – |
| Q2 2021 | $1,861,000 | -36.6% | 203,870 | -34.6% | 0.00% | – |
| Q1 2021 | $2,937,000 | +19.0% | 311,495 | -16.2% | 0.00% | – |
| Q2 2020 | $2,468,000 | +4.1% | 371,757 | -8.7% | 0.00% | – |
| Q1 2020 | $2,371,000 | +32.3% | 407,322 | +103.9% | 0.00% | – |
| Q4 2019 | $1,792,000 | – | 199,771 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 3,561,150 | $9,152,000 | 15.60% |
| Frazier Life Sciences Management, L.P. | 5,237,348 | $13,460,000 | 1.04% |
| Redmile Group, LLC | 6,952,760 | $17,869,000 | 0.69% |
| Palo Alto Investors LP | 2,330,504 | $5,989,000 | 0.47% |
| ACT CAPITAL MANAGEMENT, LLC | 47,500 | $122,000 | 0.17% |
| SkyOak Wealth, LLC | 132,851 | $341,000 | 0.12% |
| Artal Group S.A. | 750,000 | $1,928,000 | 0.08% |
| CORNERCAP INVESTMENT COUNSEL INC | 77,046 | $198,000 | 0.04% |
| CAXTON ASSOCIATES LP | 95,190 | $245,000 | 0.03% |
| XTX Topco Ltd | 50,517 | $130,000 | 0.03% |